S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Is AMC Entertainment Pulling a Fast One on the APEs?
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Here is a Simple 4 Stock Portfolio that Can Outperform the Market
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Saudi Aramco's profits already $88B as oil prices stay high
The Financial Day of Reckoning Has Begun (Ad)
NYSE:CPHI

China Pharma - CPHI Stock Forecast, Price & News

$0.23
0.00 (-0.64%)
(As of 08/12/2022 09:14 PM ET)
Add
Compare
Today's Range
$0.22
$0.24
50-Day Range
$0.21
$0.26
52-Week Range
$0.19
$0.89
Volume
111,400 shs
Average Volume
236,199 shs
Market Capitalization
$11.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CPHI stock logo

About China Pharma (NYSE:CPHI) Stock

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on shares of China Pharma in a report on Tuesday, August 9th. They issued a "hold" rating on the stock.

China Pharma Stock Performance

Shares of CPHI Stock remained flat at $0.23 during trading hours on Friday. 103,911 shares of the stock traded hands, compared to its average volume of 414,576. The business's fifty day moving average is $0.22 and its two-hundred day moving average is $0.31. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.43 and a current ratio of 0.82. China Pharma has a 52-week low of $0.19 and a 52-week high of $0.89.

China Pharma (NYSE:CPHI - Get Rating) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.02) EPS for the quarter. China Pharma had a negative return on equity of 59.21% and a negative net margin of 41.21%. The company had revenue of $1.60 million during the quarter.

Receive CPHI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for China Pharma and its competitors with MarketBeat's FREE daily newsletter.

CPHI Stock News Headlines

China Pharma (NYSE:CPHI) Coverage Initiated at StockNews.com
StockNews.com Begins Coverage on China Pharma (NYSE:CPHI)
See More Headlines
Receive CPHI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for China Pharma and its competitors with MarketBeat's FREE daily newsletter.

CPHI Company Calendar

Today
8/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
237
Year Founded
N/A

Profitability

Net Income
$-3,400,000.00
Pretax Margin
-41.19%

Debt

Sales & Book Value

Annual Sales
$9.64 million
Book Value
$0.13 per share

Miscellaneous

Free Float
24,681,000
Market Cap
$11.28 million
Optionable
Not Optionable
Beta
0.46

Key Executives

  • Ms. Zhilin Li (Age 69)
    Pres, CEO, Chairman & Interim CFO
    Comp: $241.6k
  • Ms. Huang Na C.F.A.
    BOD Sec. & IR Mang.
  • Sam Hsing
    Corp. VP













CPHI Stock - Frequently Asked Questions

How have CPHI shares performed in 2022?

China Pharma's stock was trading at $0.41 at the start of the year. Since then, CPHI stock has decreased by 43.0% and is now trading at $0.2335.
View the best growth stocks for 2022 here
.

What other stocks do shareholders of China Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China Pharma investors own include iShares Silver Trust (SLV), Check-Cap (CHEK), ContraFect (CFRX), Clear Channel Outdoor (CCO), Boxlight (BOXL), Bionano Genomics (BNGO), Athersys (ATHX), Assertio (ASRT), Ampio Pharmaceuticals (AMPE) and AMC Entertainment (AMC).

What is China Pharma's stock symbol?

China Pharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "CPHI."

How do I buy shares of China Pharma?

Shares of CPHI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is China Pharma's stock price today?

One share of CPHI stock can currently be purchased for approximately $0.23.

How much money does China Pharma make?

China Pharma (NYSE:CPHI) has a market capitalization of $11.28 million and generates $9.64 million in revenue each year. The company earns $-3,400,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

How many employees does China Pharma have?

The company employs 237 workers across the globe.

How can I contact China Pharma?

China Pharma's mailing address is 2Nd Floor, No. 17, Jinpan Road, Haikou, Hainan 570216. The official website for the company is www.chinapharmaholdings.com. The company can be reached via phone at 8689866811730, via email at hps@chinapharmaholdings.com, or via fax at 86-898-6681-9024.

This page (NYSE:CPHI) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.